ACLY and metabolic dysfunction-associated steatotic liver disease: TA administration showed anti-lipogenic effects, by blocking the hyperacetylation of lysine 9 and 36 at histone H3 (H3K9 and H3K36) in the promoter of DNL genes (SREBP1c, FASN and ATP citrate lyase (ACLY)), thus improving NAFLD [120,122].